Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study

References

• Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature Rev Microbiol. 2023;21(3):162–177. doi: 10.1038/s41579-022-00841-7
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L. The therapeutic potential of natural dietary flavonoids against SARS-CoV-2 infection. Nutrients. 2023;15(15):3443. doi: 10.3390/nu15153443
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L. Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: strategies, benefits, and challenges. J med virol. 2022;94(4):1373–1390. doi: 10.1002/jmv.27517
   PubMed Web of Science ®Google Scholar
• Rabie AM. Improved Synthesis of the Anti-SARS-CoV-2 Investigational Agent (E)-N-(4-Cyanobenzylidene)-6-fluoro-3-hydroxypyrazine-2-carboxamide (Cyanorona-20). Revista de Chimie. 2022;73(4):69–75. doi: 10.37358/RC.22.4.8555
   Google Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega. 2023;8(6):5234–5246. doi: 10.1021/acsomega.2c03881
   PubMedGoogle Scholar
• Rabie AM. Future of the current anticoronaviral agents: A viewpoint on the validation for the next COVIDs and pandemics. Biocell. 2023;47(10):2133–2139. doi: 10.32604/biocell.2023.030057
   Web of Science ®Google Scholar
• Rabie AM. Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoVitris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. New J Chem. 2021;45(2):761–771. doi: 10.1039/D0NJ03708G
   Web of Science ®Google Scholar
• Rabie AM. Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19. Current Res Pharmacol Drug Discov. 2021;2:100055. doi: 10.1016/j.crphar.2021.100055
   PubMedGoogle Scholar
• Rabie AM. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. Chem Biol Interact. 2021;343:109480. doi: 10.1016/j.cbi.2021.109480
   PubMed Web of Science ®Google Scholar
• Rabie AM. Potent inhibitory activities of the adenosine analogue cordycepin on SARS-CoV-2 replication. ACS Omega. 2022;7(3):2960–2969. doi: 10.1021/acsomega.1c05998
   PubMed Web of Science ®Google Scholar
• Kozlov M. Why scientists are racing to develop more COVID antivirals. Nature. 2022;601(7894):496. doi: 10.1038/d41586-022-00112-8
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542
   PubMed Web of Science ®Google Scholar
• Arbel R, Wolff Sagy Y, Hoshen M, et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N Engl J Med. 2022;387(9):790–798. doi: 10.1056/NEJMoa2204919
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zheng B, Han B, et al. Is Azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy and safety for hospitalized patients with COVID-19? a retrospective cohort study. Infect Dis Ther. 2023;12(8):2087–2102. doi: 10.1007/s40121-023-00845-7
   PubMed Web of Science ®Google Scholar
• Chen R, Guo Y, Deng S, et al. All-cause mortality in moderate and severe COVID-19 patients with myocardial injury receiving versus not receiving azvudine: a propensity score-matched analysis. Cardiology Plus. 2023;8(2):103–110. doi: 10.1097/CP9.0000000000000049
   PubMedGoogle Scholar
• Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681–1693. doi: 10.1016/S1473-3099(22)00507-2
   PubMed Web of Science ®Google Scholar
• Xu N, Yang J, Zheng B, et al. The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses. J Virol. 2020;94(9):e00204–e00220. doi: 10.1128/JVI.00204-20
   PubMed Web of Science ®Google Scholar
• Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduct Target Ther. 2020;5(1):236. doi: 10.1038/s41392-020-00351-z
   PubMed Web of Science ®Google Scholar
• Han X, Gao D, Li C, et al. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study. BMC Infect Dis. 2024;24(1):57. doi: 10.1186/s12879-023-08965-8
   PubMedGoogle Scholar
• Wang J, Xu W, Jin P. The first independently developed drug for the treatment of novel coronavirus pneumonia in China-Azvudine. Chinese J Pharm. 2022;57(23):2041–2044. doi: 10.11669/cpj.2022.23.013
   Google Scholar
• Zhou Z, Zheng H, Ge X, et al. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study. BMC Infect Dis. 2024;24(1):47. doi: 10.1186/s12879-023-08944-z
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L, Song XQ. Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol. 2022;13:1015355. doi: 10.3389/fimmu.2022.1015355
   PubMed Web of Science ®Google Scholar
• Qi X, Yang Y, Gong B, et al. Real-world effectiveness of azvudine for patients infected with the SARS-CoV-2 omicron subvariant BA.5 in an intensive care unit. J Thoracic Dis. 2023;15(9):4925–4937. doi: 10.21037/jtd-23-1093
   PubMed Web of Science ®Google Scholar
• Sarkar C, Mondal M, Torequl Islam M, et al. Potential therapeutic options for COVID-19: current status, challenges, and future perspectives. Front Pharmacol. 2020;11:572870. doi: 10.3389/fphar.2020.572870
   PubMed Web of Science ®Google Scholar
• Wang RR, Yang QH, Luo RH, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLOS ONE. 2014;9(8):e105617. doi: 10.1371/journal.pone.0105617
   PubMed Web of Science ®Google Scholar
• Wei AH, Zeng L, Wang L, et al. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching. Front Pharmacol. 2023;14:1274294. doi: 10.3389/fphar.2023.1274294
   PubMed Web of Science ®Google Scholar
• de SouzaSB, Cabral PGA, da Silva RM, et al. Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients. Front Med (Lausanne). 2023;10:1215916. doi: 10.3389/fmed.2023.1215916
   PubMedGoogle Scholar
• Zhang JL, Li YH, Wang LL, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):414. doi: 10.1038/s41392-021-00835-6
   PubMed Web of Science ®Google Scholar
• Sun Y, Jin L, Dian Y, et al. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. eClinicalmedicine. 2023;59:101981. doi: 10.1016/j.eclinm.2023.101981
   PubMedGoogle Scholar
• Shang S, Fu B, Geng Y, et al. Azvudine therapy of common COVID‐19 in hemodialysis patients. J med virol. 2023;95(8):e29007. doi: 10.1002/jmv.29007
   PubMed Web of Science ®Google Scholar
• Yang H, Wang Z, Jiang C, et al. Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: results of a real‐world study. J med virol. 2023;95(7):e28947. doi: 10.1002/jmv.28947
   PubMed Web of Science ®Google Scholar
• Yang L, Wang Z. Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China. Eur J Med Chem. 2023;257:115503. doi: 10.1016/j.ejmech.2023.115503
   PubMed Web of Science ®Google Scholar
• Dian Y, Meng Y, Sun Y, et al. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. J Infect. 2023;87(2):e24–e27. doi: 10.1016/j.jinf.2023.05.012
   PubMed Web of Science ®Google Scholar
• Deng G, Li D, Sun Y, et al. Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study. J med virol. 2023;95(4):e28756. doi: 10.1002/jmv.28756
   PubMed Web of Science ®Google Scholar
• Gao Y, Luo Z, Ren S, et al. Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19. J Infect. 2023;86(6):e158–e160. doi: 10.1016/j.jinf.2023.03.023
   PubMed Web of Science ®Google Scholar
• Zhao X, Cheng Y, Zhang M, et al. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study. Infect Drug Resist. 2023;16:6053–6060. doi: 10.2147/IDR.S423725
   PubMed Web of Science ®Google Scholar
• Jiang J. Study on Azvudine, a New Anti COVID-19 Drug. Chin J Med Guide. 2022;24(10):947–948. doi: 10.3969/j.issn.1009-0959.2022.10.001
   Google Scholar
• Chang J. Research progress of oral small molecule drugs for COVID-19. Science China. 2022;36(4):630–634. doi: 10.16262/j.cnki.1000-8217.20220829.013
   Google Scholar
• Wang X, Dian Y, Zhou Q, et al. Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study. Front Immunol. 2023;14:1320973. doi: 10.3389/fimmu.2023.1320973
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Guidelines on the diagnosis and treatment of COVlD-19 (10th ed.). 2023. Available from: http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml
   Google Scholar
• Hu CY, Cui WS, Lei Y, et al. Comparison of Azvudine and nirmatrelvir/ritonavir and combined use in patients with COVID-19. Infect Drug Resist. 2023;16:7797–7808. doi: 10.2147/IDR.S433186
   PubMed Web of Science ®Google Scholar
• Su P, Yang CX, Wang XG. Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients. BMC Infect Dis. 2024;24(1):44. doi: 10.1186/s12879-023-08828-2
   PubMed Web of Science ®Google Scholar
• Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of Post-COVID-19 Condition. JAMA Intern Med. 2023;183(6):554–564. doi: 10.1001/jamainternmed.2023.0743
   PubMed Web of Science ®Google Scholar
• Fung KW, Baye F, Baik SH, et al. Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients. JAMA Intern Med. 2023;183(12):1404–1406. doi: 10.1001/jamainternmed.2023.5099
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Q, Xu C, et al. Differences in clinical characteristics and liver injury between patients diagnosed with the Omicron subvariant BA.5.2 and the prototype of SARS-CoV-2: a single center retrospective study. BMC Gastroenterol. 2023;23(1):271. doi: 10.1186/s12876-023-02907-z
   PubMed Web of Science ®Google Scholar
• Wang K, Guo Z, Zeng T, et al. Transmission characteristics and inactivated vaccine effectiveness against transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China. JAMA Netw Open. 2023;6(3):e235755. doi: 10.1001/jamanetworkopen.2023.5755
   PubMed Web of Science ®Google Scholar
• COVID-19 Clinical and Surveillance Data — December 9, 2022 to April 27, 2023, China. 2023. Available from: https://weekly.chinacdc.cn/news/covid-surveillance/f9be9fe5-1684-46db-aa88-0a35c3aa2805_en.htm
   Google Scholar
• Renoux C, Azoulay L, Suissa S. Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: designing real-world evidence studies. Am J Epidemiol. 2021;190(8):1452–1456. doi: 10.1093/aje/kwab028
   PubMed Web of Science ®Google Scholar
• Flury BK, Hjas R. Standard distance in univariate and multivariate analysis. Am Stat. 1986;40(3):249–251. doi: 10.1080/00031305.1986.10475403
   Web of Science ®Google Scholar
• Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat - Sim Comp. 2009;38(6):1228–1234. doi: 10.1080/03610910902859574
   Web of Science ®Google Scholar
• Weng C, Xie R, Han G, et al. Safety and Efficacy of paxlovid against omicron variants of coronavirus disease 2019 in Elderly Patients. Infect Dis Ther. 2023;12(2):649–662. doi: 10.1007/s40121-023-00760-x
   PubMed Web of Science ®Google Scholar
• Team RC. R: A language and environment for statistical computing. MSOR Connections. 2014;1:12–21. Available from: https://api.semanticscholar.org/CorpusID:215755663
   Google Scholar
• Ho D, Imai K, King G, et al. MatchIT: Nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42(8):1–28. doi: 10.18637/jss.v042.i08
   Web of Science ®Google Scholar
• Perme MP, Pavlic K. Nonparametric relative survival analysis with the R package relsurv. J Stat Softw. 2018;87(8):1–27. doi: 10.18637/jss.v087.i08
   Web of Science ®Google Scholar
• Rabie AM. Efficacious preclinical repurposing of the nucleoside analogue didanosine against COVID-19 polymerase and exonuclease. ACS Omega. 2022;7(25):21385–21396. doi: 10.1021/acsomega.1c07095
   PubMed Web of Science ®Google Scholar
• Rabie AM. The informative nature of the disappeared sars-cov-2 genomic sequences: a mini-review with perspectives. Adv Chem Res. 2022;1(2):58–64. doi: 10.37256/acbr.1220221403
   Google Scholar
• Rabie AM. New potential inhibitors of coronaviral main protease (CoV-Mpro): Strychnine bush, pineapple, and ginger could be natural enemies of COVID-19. Int J New Chem. 2022;9(3):225–237. doi: 10.22034/ijnc.2022.3.10
   Google Scholar
• Rabie AM. RNA: The most attractive target in recent viral diseases. Chem Biol Drug Des. 2024;103(1):e14404. doi: 10.1111/cbdd.14404
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdalla M. Forodesine and riboprine exhibit strong anti-SARS-CoV-2 repurposing potential: in silico and in vitro studies. ACS Bio Med Chem Au. 2022;2(6):565–585. doi: 10.1021/acsbiomedchemau.2c00039
   PubMedGoogle Scholar
• Rabie AM, Abdalla M. Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the omicron-B.1.1.529/BA.2 subvariant: a repurposing research study. Med Chem Res. 2023;32(2):326–341. doi: 10.1007/s00044-022-02970-3
   PubMed Web of Science ®Google Scholar
• Rabie AM, Abdel-Dayem MA, Abdalla M. Promising experimental anti-SARS-CoV-2 agent “SLL-0197800”: the prospective universal inhibitory properties against the coming versions of the coronavirus. ACS Omega. 2023;8(39):35538–35554. doi: 10.1021/acsomega.2c08073
   PubMed Web of Science ®Google Scholar
• Rabie AM, Eltayb WA. Potent dual polymerase/exonuclease inhibitory activities of antioxidant aminothiadiazoles against the COVID-19 omicron virus: a promising in silico/in vitro repositioning research study. Mol Biotechnol. 2024;66(4):592–611. doi: 10.1007/s12033-022-00551-8
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie H, Wang L, et al. Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis. Virol J. 2024;21(1):46. doi: 10.1186/s12985-024-02316-y
   PubMed Web of Science ®Google Scholar
• Xinjie H, Xiaobo H, Yongqian W, et al. Effectiveness and optimal timing of azvudine in COVID-19 patients: a multi-center retrospective study in beijing, china. Res Square. 2023:1–15. doi: 10.21203/rs.3.rs-3145554/v1
   Google Scholar
• Shen M, Xiao C, Sun Y, et al. Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study. medRxiv. 2023:1–16. doi: 10.1101/2023.01.23.23284899
   Google Scholar
• Kaican Z, Hui Z, Wen L, et al. Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study. Acta Pharm Sin B. 2023;13(11):4655–4660. doi: 10.1016/j.apsb.2023.07.007
   PubMed Web of Science ®Google Scholar
• Wong CKH, Lau JJ, Au ICH, et al. Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation. Nat Commun. 2023;14(1):8377. doi: 10.1038/s41467-023-43706-0
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Degli Antoni M, Minisci D, et al. The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study. Infection. 2023;51(6):1633–1644. doi: 10.1007/s15010-023-02028-5
   PubMed Web of Science ®Google Scholar